Study Summary
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies. A total of 30 patients are planned to be enrolled over a period of 2 years.
Interested in this trial?
Submit an InquiryInterventions
Autologous CAR-TBIOLOGICAL
Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hematology Department, Hebei Medical University Fourth Hospital | Shijiazhuang | Hebei | China |